Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart

Circulation: Heart Failure

Volumn 6, Issue 3, 2013, Pages 535-543

  Divakaran, Vijay G ^b   Evans, Sarah ^a   Topkara, Veli K ^a   Diwan, Abhinav ^a   Burchfield, Jana ^b   Gao, Feng ^b   Dong, Jianwen ^b   Tzeng, Huei Ping ^a   Sivasubramanian, Natarajan ^b   Barger, Philip M ^a   Mann, Douglas L ^a  

^a Center for Cardiovascular Research   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dilated cardiomyopathy; Inflammation; TNF receptor associated factor 2; Tumor

Indexed keywords

FIBRILLAR COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MYOSIN HEAVY CHAIN; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MUSCLE FIBRIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SARCOMERE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ULTRASTRUCTURE; UPREGULATION;

DILATED CARDIOMYOPATHY; INFLAMMATION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR SUPERFAMILY;

ANIMALS; APOPTOSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MUSCLE CELLS; NF-KAPPA B; PHENOTYPE; TNF RECEPTOR-ASSOCIATED FACTOR 2; VENTRICULAR REMODELING;

EID: 84879226604     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.000080     Document Type: Article

References (29)

1. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826-831.
2. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627-635.
3. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375-1381.
4. Ueland T, Aukrust P, Damas JK, Gullestad L, Yndestad A. The tumor necrosis factor superfamily in heart failure. Future Cardiol. 2006;2:101-111.
5. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R, Burkly LC. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation. 2009;119:2058-2068.
6. Ueland T, Yndestad A, ∅ie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/ RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468.
7. Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000;105:1199-1208.
8. Gupta S, Sen S. Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts. J Mol Med. 2005;83:993-1004.
9. Burchfield JS, Dong JW, Sakata Y, Gao F, Tzeng HP, Topkara VK, Entman ML, Sivasubramanian N, Mann DL. The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptorassociated factor 2 in the heart. Circ Heart Fail. 2010;3:157-164.
10. Haudek SB, Taffet GE, Schneider MD, Mann DL. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 2007;117:2692-2701.
11. Sakata Y, Chancey AL, Divakaran VG, Sekiguchi K, Sivasubramanian N, Mann DL. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol. 2008;103:60-68.
12. Nemoto S, Vallejo JG, Knuefermann P, Misra A, Defreitas G, Carabello BA, Mann DL. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol. 2002;282:H2316-H2323.
13. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004;109:262-268.
14. Engel D, Peshock R, Armstong RC, Sivasubramanian N, Mann DL. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol. 2004;287:H1303-H1311.
15. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat. 2002;200:69-79.
16. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861-874.
17. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57.
18. Panagopoulou P, Davos CH, Milner DJ, Varela E, Cameron J, Mann DL, Capetanaki Y. Desmin mediates TNF-alpha-induced aggregate formation and intercalated disk reorganization in heart failure. J Cell Biol. 2008;181:761-775.
19. Mann DL. Cytokines as mediators of disease progression in the failing heart. In Hosenpud JD, Greenberg BH, (eds). Congestive Heart Failure. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:205-225.
20. Broqvist M, Dahlström U, Karlberg BE, Karlsson E, Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989;10:1075-1083.
21. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptorassociated factors (TRAFs): a family of adapter proteins that regulates life and death. Genes Dev. 1998;12:2821-2830.
22. Hodgson DM, Zingman LV, Kane GC, Perez-Terzic C, Bienengraeber M, Ozcan C, Gumina RJ, Pucar D, O'Coclain F, Mann DL, Alekseev AE, Terzic A. Cellular remodeling in heart failure disrupts K(ATP) channeldependent stress tolerance. EMBO J. 2003;22:1732-1742.
23. Xia ZP, Chen ZJ. TRAF2: a double-edged sword? Sci STKE. 2005;2005:pe7.
24. Higuchi Y, Chan TO, Brown MA, Zhang J, DeGeorge BR Jr, Funakoshi H, Gibson G, McTiernan CF, Kubota T, Jones WK, Feldman AM. Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol. 2006;290:H590-H598.
25. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, Cong R, Franzoso G. Induction of gadd45beta by NF-kappaB downregulates proapoptotic JNK signalling. Nature. 2001;414:308-313.
26. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
27. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
28. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.
29. Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets. 2011;11:347-356.